Freenome, Inc.
corporate_fare Company Profile
Freenome, Inc. (NASDAQ:FRNM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 7 items for FRNM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for FRNM spans 10-Q, S-1, 8-K/A.
Recent high-impact activity:
- Freenome Posts $60.1M Q3 Profit on $183.5M Revenue; $430M Cash Funds Runway Into 2028
- Freenome Swings to $60M Profit on $183.5M Q3 Revenue After FDA Nod
- Freenome Launches SimpleScreen Lung, Bundles Lung and CRC Screening in One Blood Draw
- Freenome Registers 75.1M Shares for Resale by Existing Holders, Creating Significant Stock Overhang
- Freenome Files Amended 8-K with First Post-Merger Financials and Pro Forma Data
Financial Snapshot
Short Interest & Short Volume
8.08 days to coverFINRA reported short interest of 4,633,222 shares in FRNM as of the October 30, 2026 settlement, a 3.4% increase from the prior period — about 8.1 days to cover at its recent average daily volume. On November 20, 2026, 41.7% of FRNM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for FRNM, detected from its recent SEC filings.
Massive Share Resale Registration · Minimal Proceeds to Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →